Highest-materiality recent filing
Eloxx Pharma: 1-for-11 reverse stock split effective May 29; appoints two independent directors
Board approved 1-for-11 reverse stock split effective May 29, 2026; authorized shares reduced from 500M to 100M.
Ratified amendment to 2018 Equity Plan: shares available increased to 20M, ISO limit to 30M.
Eloxx enters $3.2M debt amendment with Hercules and Domicilium; Royalty obligations up to $53M
Tranche 2 Advance of $3.175M provided under Sixth Amendment to Hercules loan; Bridge Loan of $288k also made.
Eloxx inks exclusive license deal with Almirall for ZKN-013; $3M upfront, up to $470M milestones
Upfront payment of $3.0 million; eligible for up to $470.0 million in regulatory and sales milestones.
Eloxx Pharmaceuticals restructures debt; issues stock and warrants for $2M loan assignment
Entered Fifth Amendment to Hercules Loan Agreement; $2M Tranche 1B Advance assigned to SD MF 4 LLC.
Eloxx amends Hercules loan, repays $1M; cash covenant lowered to $1.05M through Jan 2024
Minimum qualified cash reduced to $1.05M from Dec 15, 2023 to Jan 25, 2024.
Net loss of $3.6M ($1.31/share) vs. $7.5M loss a year ago; R&D expenses down to $1.3M from $4.9M.
Eloxx receives Nasdaq delisting notice; trading suspended Oct 16, shares to OTC
Nasdaq notified Eloxx on Oct 12, 2023 that it failed to regain compliance with $35M MVLS rule.
Eloxx reports positive kidney biopsy results from Phase 2 ELX-02 trial in Alport syndrome
Three patients showed improvement in foot process effacement on TEM kidney biopsies after 8 weeks of ELX-02 treatment.
Eloxx Pharma R&D head Dr. Vijay Modur resigns effective Sept 30, 2023
Dr. Vijay Modur, Head of R&D, notified resignation effective September 30, 2023.
Eloxx submits IND for ELX-02 in Alport syndrome; Phase 2 data show remission in 1 of 3 patients
Submitted IND to FDA for ELX-02 to treat Alport syndrome with nonsense mutations.
Eloxx Pharma Q2 net loss $4.3M; cash only into Q4 2023; ELX-02 positive biopsy data
Net loss of $4.3M ($1.96 EPS) vs $10.6M ($4.90 EPS) in prior-year quarter.
Eloxx receives Nasdaq extension to Oct 9, 2023 to meet $35M market value rule
Nasdaq Hearings Panel extended compliance deadline for Listing Rule 5550(b)(2) from July 30 to October 9, 2023.
Eloxx reports ELX-02 Phase 2 data: partial remission in 1 of 3 Alport patients
Patient 4401-02 showed ~49% average reduction in UPCR (p=0.009) after 8 weeks of ELX-02.
Eloxx reports Phase 2 CF data: ELX-02 shows +2.83% ppFEV1 in 6 responders, supports pivotal trial
13 evaluable patients; 6 responders had +2.83% mean ppFEV1 increase at Day 35 vs Day 1.
Eloxx gets Nasdaq extension to July 30, 2023 for continued listing; ELX-02 pivotal study planned
Nasdaq Hearings Panel granted extension through July 30, 2023 to regain compliance with $35M market value rule.
Eloxx reports ELX-02 Phase 2 topline: one patient remission; opens $50M ATM offering
One of two completed patients achieved remission (≥50% UPCR decline); five of eight readings averaged 53% below baseline.
Eloxx Q1 net loss narrows to $6.2M; cash runway into Q3 2023
Net loss of $6.2M ($2.88/sh) vs $11.6M ($5.36/sh) in Q1 2022; R&D and G&A expenses decreased.
Eloxx receives Nasdaq delisting notice for failing to maintain $35M market value
Received delisting notice on April 11, 2023, for non-compliance with Nasdaq's $35M minimum market value requirement.
Eloxx reports Q4 net loss $6.3M, cash $19.2M; Phase 2 Alport study ongoing, IND filed for ZKN-013
Net loss $6.3M ($2.92/share) vs $12.1M loss in Q4 2021; R&D and G&A expenses decreased YoY.
Eloxx Q3 net loss $7.5M ($0.09/share); Alport Phase 2 trial started, CF combo misses endpoints
Net loss of $7.5M vs $9.9M in prior-year quarter; R&D expense $4.9M, G&A $2.3M.
Eloxx warned by Nasdaq: MVLS below $35M, faces potential delisting
Received Nasdaq notice on Oct 11, 2022; MVLS below $35M minimum for 30 consecutive business days.
Eloxx Phase 2 ELX-02 CF trial misses efficacy endpoints; lung exposure low
Combination of ELX-02 with ivacaftor did not achieve statistical significance for changes in SCC or FEV1.
Eloxx Q2 net loss $10.6M; cash $30M; CF topline data expected Q3 2022
Q2 2022 net loss $10.6M ($0.12/sh) vs $36.1M ($0.54/sh) in Q2 2021; prior year included $22.7M Zikani acquisition expense.
Five directors (Gadi Veinrib, Ran Nussbaum, Zafrira Avnur, Rajesh Parekh, Jasbir Seehra) resign effective July 1, 2022.
Eloxx Q4 net loss $12.1M; CF Foundation awards up to $15.9M; new Alport program
Net loss $12.1M in Q4 2021 ($0.14/sh); cash $42.3M; expects funding into Q2 2023.
Closing bid price of common stock below $1.00 for 30 consecutive business days as of Jan 3, 2022.
Eloxx Phase 2 ELX-02 monotherapy shows 5.4 mmol/L sweat chloride reduction; advancing to Phase 3
Statistically significant 5.4 mmol/L mean sweat chloride reduction at 1.5 mg/kg/day (p=0.022) in Class 1 CF patients with G542X mutation.
Eloxx reports Q3 net loss of $9.9M; Phase 2 CF data on track for Q4 2021
Net loss of $9.9M ($0.11/share) vs $6.6M loss; R&D spending rose to $5.2M.
Eloxx enters $50M at-the-market equity distribution agreement with SVB Leerink
Up to $50M in common stock may be sold through SVB Leerink as sales agent under ATM program.
Eloxx reports Q2 net loss of $36.1M, cash $56.7M; CF trial on track for Q4 data
Net loss $36.1M ($0.54/sh) vs $7.9M ($0.20/sh) in Q2 2020; includes $22.7M acquired IPR&D from Zikani.
Eloxx updates Phase 2 ELX-02 progress; COO Neil Belloff to depart by Aug 25
Neil Belloff, COO and General Counsel, will transition and depart on or before August 25, 2021; will receive base salary and benefits through departure.
the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board
the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board
Mr. Tomer Kariv notified the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) of his resignation from the Board and his position as Chairman of the Board and from the committee of the Board on which he serves.
On September 15, 2023, Dr. Vijay Modur, Head of Research and Development of Eloxx Pharmaceuticals, Inc. (the “Company”), notified the Company of his resignation effective September 30, 2023.
On June 30, 2022, each of Zafrira Avnur, Rajesh Parekh and Gadi Veinrib notified the Board of their respective resignations from the Board and the respective committees of the Board on which they serve.
On June 30, 2022, each of Zafrira Avnur, Rajesh Parekh and Gadi Veinrib notified the Board of their respective resignations from the Board and the respective committees of the Board on which they serve.
On June 30, 2022, each of Zafrira Avnur, Rajesh Parekh and Gadi Veinrib notified the Board of their respective resignations from the Board and the respective committees of the Board on which they serve.
On June 28, 2022, each of Ran Nussbaum and Jasbir Seehra notified the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) of their respective resignations from the Board and the respective committees of the Board on which they serve.
On June 28, 2022, each of Ran Nussbaum and Jasbir Seehra notified the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) of their respective resignations from the Board and the respective committees of the Board on which they serve.
On June 30, 2022, the Board appointed Lindsay Androski to serve as a director on the Company’s Board to fill the remaining vacancy and as a member of the Board’s Audit Committee and Compensation Committee, in each case, effective as of the Effective Time.
On August 17, 2021, the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed the Company’s Interim Chief Financial Officer, Daniel Geffken, to serve as the Company’s Principal Accounting Officer.
On July 14, 2021, Eloxx Pharmaceuticals, Inc. (the “Company”) was advised by Mr. Gary Rakers of his intention to resign as the Company’s Executive Director, Finance & Accounting, Corporate Conroller and Treasurer (Principal Accounting Officer) effective July 30, 2021.
Max materiality 1.00 · Median 0.60 · Most common event other_material